

November 9, 2010



SCYNEXIS Receives Merial Research Collaboration Milestone Payment

RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- 11/09/10 -- Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a fourth payment for meeting certain milestones in a multi-year research collaboration which began in 2005.

SCYNEXIS, a premier drug discovery and development company, directs considerable medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial's animal health discovery efforts.

"SCYNEXIS is pleased to earn another important research milestone through our valued partnership with Merial," said SCYNEXIS President and Chief Executive Officer Dr. Yves Ribeill. "This is the fourth consecutive milestone we have reached for delivering significant, innovative animal health development candidates to Merial under the agreement."

"Merial is delighted to see this latest success resulting from our pharmaceutical discovery collaboration with SCYNEXIS. This exciting addition to Merial's pharmaceutical pipeline shows what can be achieved when the best outside skills and resources are combined with Merial's in-house knowledge and expertise," said Dr. Christian Miculka, Head Discovery & Research.

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2009 sales were \$2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis. For more information, please see www.merial.com.

About SCYNEXIS

SCYNEXIS delivers integrated, efficient and innovative drug discovery and development solutions to our global health and pharmaceutical partners. Our record of success is exemplified by the delivery of eleven pre-clinical drug candidates over the last five years. SCYNEXIS' teams are tailored to be especially effective in moving customer projects from concept to clinic, utilizing powerful proprietary technologies such as the HEOS® SaaS Software Platform for comprehensive drug discovery information management and the MEDCHEM-FACTORY® High-Throughput Synthesis and Purification Platform.

Our fully-integrated contract research solutions include medicinal chemistry, advanced biological screening, in vitro pharmacology and ADMET, DMPK, bioanalytical and analytical chemistry, process chemistry, and cGMP manufacturing.

Our process chemistry department has achieved positive outcomes with general inspection and pre-approval inspection (PAI) by the FDA in support of customer NDA.

Founded in 2000, SCYNEXIS is located in Research Triangle Park, N.C. SCYNEXIS is registered with both the FDA and DEA. Please visit our website at www.scynexis.com.

®HEOS and MEDCHEM-FACTORY are registered trademarks of SCYNEXIS, Inc.

For further information, please contact:

SCYNEXIS, Inc.

Terry Marquardt

Executive Director

Market Development & Communications

[Email Contact](#)

Tel: +1-919-544-8603

SCYNEXIS Media Contacts:

Rick Rountree

Rick Rountree Communications, Inc.

[Email Contact](#)

Tel. +1 919-878-1144

Sarah Cavanaugh

MacDougall Biomedical Communications

[Email Contact](#)

Tel. +1 781-235-3060